false
0001641631
0001641631
2024-11-11
2024-11-11
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): November 11, 2024
Beyond
Air, Inc.
(Exact
Name of Registrant as Specified in Charter)
Delaware |
|
001-38892 |
|
47-3812456 |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
900
Stewart Avenue, Suite 301
Garden
City, NY 11530
(Address
of Principal Executive Offices and Zip Code)
(516)
665-8200
Registrant’s
Telephone Number, Including Area Code
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
|
☐ |
Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $.0001 per share |
|
XAIR |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405)
or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02. Results of Operations and Financial Condition.
On
November 11, 2024, Beyond Air, Inc. (the “Company”) issued a press release announcing financial results for its fiscal quarter
ended September 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1, and is incorporated herein by reference.
This
information, including the exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall
be expressly set forth by specific reference in such filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
BEYOND
AIR, Inc. |
|
|
|
Date:
November 18, 2024 |
By: |
/s/
Steven A. Lisi |
|
Name:
|
Steven
A. Lisi |
|
Title |
Chief
Executive Officer |
Exhibit
99.1
Beyond
Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update
Revenues
increased 17% compared to the previous quarter ended June 30, 2024
Strengthened
balance sheet is expected to provide sufficient cash runway through June 2026
Completed
a $20.6 million private placement offering with multiple healthcare-focused institutional funds and Company insiders
Retired
$17.5 million in debt from Avenue Capital and entered into a $11.5 million loan agreement with an insider-led investor group
Conference
call scheduled for 4:30 p.m. ET today, November 11th
Garden
City, NY, November 11, 2024 – Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”),
a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives
of patients, today announced its financial results for the fiscal second quarter ended September 30, 2024, and provided a corporate update.
“Our
commercial strategy continued to drive results throughout the quarter with our total number of customers increasing by over 60%,”
said Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. “We believe this is just the beginning of a pivotal year for
our Company as we leverage our expanding network of reference customers that have implemented LungFit PH in their hospitals. We have
a strong foundation of customer success stories that speak to the cost savings, workflow improvements and additional value our technology
delivers in a real-world setting, compared to traditional cylinder-based systems. In addition, since joining our team four months ago,
our new Chief Commercial Officer, David Webster, has won key partners to rapidly accelerate our topline growth, including TrillaMed,
Healthcare Links and Business Asia Consultants, among others, resetting our commercial strategy and reorganizing our sales, marketing
and support teams.”
Lisi
added: “Our executive team and board of directors have taken decisive actions this year to enhance the Company’s financial
health and commercial execution as we continue accelerating our revenue growth. We recently implemented a capital conservation strategy
to preserve cash, executed a series of financial transactions that increased our capital resources and eliminated approximately $12 million
in debt-related payments through mid-2026. We are confident that these strategic initiatives, in conjunction with projected revenue growth,
will extend our cash runway to support our current operating plans through June 2026.”
Recent
Commercial Execution, Portfolio Highlights and Upcoming Milestones
LungFit®
PH
| ○ | Increased
commercial demand for LungFit PH, as evidenced by: |
| § | A
17% increase in revenue for the quarter ended September 30, 2024, compared with the previous
quarter ended June 30, 2024 |
| § | The
number of hospital contracts increased by 60% over the course of the second fiscal quarter
of 2025 |
| § | Announced
the U.S. Naval Hospital Guam has deployed the LungFit PH system in its mission to provide
top-tier neonatal care |
| § | Annualized
contracted revenue was $3.5 million on October 1, 2024; with an additional four hospitals
slated to start later in fiscal 3Q 2025 further increasing the annualized run rate |
| ○ | Entered
a strategic partnership with Healthcare Links, a renowned healthcare advisory and contracting
firm, that will focus on expanding access to the LungFit® PH system by streamlining entry
into Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs) across
the United States |
| ○ | Partnered
with Business Asia Consultants, Inc. - an international sales, marketing and business development
consulting company with extensive experience in Europe, the Pacific Rim and Latin America
- to help accelerate the global expansion of the LungFit PH |
| ○ | Partnered
with TrillaMed, a premier provider of medical supplies and technologies to government and
healthcare systems globally, to bring LungFit PH to the U.S. Veterans Administration and
Department of Defense hospitals |
| ○ | Cardiac
surgery PMA supplement review ongoing at FDA |
| § | Currently
no FDA approved nitric oxide system is labeled for cardiac surgery |
| § | Approval
would increase LungFit PH’s rate of market penetration and support long-term revenue
growth |
| ○ | A
decision on CE Mark for LungFit PH in Europe expected before year-end 2024 |
| ○ | LungFit
PH transport-ready PMA supplement submission to FDA anticipated in CY 1Q 2025 |
Beyond
Cancer - Solid Tumor Program
| ● | Clinical
Development Execution |
| ○ | Ultra-high
concentration Nitric Oxide (UNO) therapy is in an ongoing Phase 1a trial evaluating advanced,
relapsed or refractory unresectable, primary or metastatic cutaneous and subcutaneous solid
tumors |
| § | Promising
preclinical data presented in two posters at the Society for Immunotherapy of Cancer (SITC)
Annual Meeting 2024 showed the efficacy of low volume (LV) UNO – less than 10% of the
UNO dose that showed an acceptable safety profile in the ongoing Phase 1a study – when
combined with immune checkpoint inhibitors. In a study using MAT B III tumor-bearing rats,
LV UNO combined with anti-rPD-L1 doubled the tumor growth inhibition rate and led to improved
survival outcomes compared to anti-rPD-L1 alone. Based on these data, the Beyond Cancer team
believes LV UNO may positively influence PD-1 progressors and broaden the pool of patients
who could benefit from immunotherapy, including those previously ineligible for treatment |
| § | Upon
clearance from regulators in Israel, expected shortly, a Phase 1b trial is planned to enroll
up to 20 subjects with prior exposure to anti-PD-1 antibody that have either progressed,
not achieved a response, or have prolonged stable disease (≥ 12 weeks) on single agent
anti-PD-1 without radiographic evidence of continued tumor reduction. Subjects enrolled in
the Phase 1b trial will be treated with UNO + anti-PD-1 combination |
| ● | Beyond
Cancer intends to seek additional capital to perform human studies in addition to the planned
Phase Ib trial |
Recent
Corporate Updates
| ● | Completed
a private placement offering for gross proceeds of approximately $20.6 million, which included
participation by multiple healthcare-focused institutional funds, as well as Company insiders |
| ● | Retired
$17.5 million in Avenue Capital debt, eliminating approximately $12 million in debt-related
payments through June 2026. In addition, Avenue Capital invested $3.35 million in the private
placement offering |
| ● | Entered
into an $11.5 million loan agreement with an insider-led investor group, which utilizes an
8% royalty on net sales beginning in July 2026 to repay the loan. The royalty would cease
upon complete loan repayment |
Financial
Results for the Fiscal Second Quarter Ended September 30, 2024
Revenues
for the fiscal quarter ended September 30, 2024 were $0.8 million compared to $0.2 million for the fiscal quarter ended September 30,
2023 and $0.7 million for the previous quarter ended June 30, 2024. Cost of revenue of $1.9 million was recognized for the three months
ended September 30, 2024, compared to $0.4 million for the three months ended September 30, 2023. Cost of revenue exceeded revenue primarily
driven by depreciation of LungFit devices and one-time upgrade costs to systems.
Research
and development expenses for the three months ended September 30, 2024, were $4.6 million as compared to $7.1 million for the three months
ended September 30, 2023. The decrease of $2.5 million was primarily attributed to a decrease in salaries, stock-based compensation and
pre-clinical studies expenses.
Selling,
general and administrative expenses for the three months ended September 30, 2024 and September 30, 2023 were $7.2 million and $10.2
million, respectively. The decrease of $3.0 million was attributed primarily to a reduction in stock-based compensation cost.
Other
income and expense for the three months ended September 30, 2024 was a loss of $1.2 million compared to a gain of $0.1 million for the
three months ended September 30, 2023. The decrease of $1.3 million was mainly due to the impact of the partial retirement of the Avenue
Capital debt. Cash burn in the fiscal quarter ended September 30, 2024, excluding financing and one-time items was $11.5 million.
As
of September 30, 2024, the Company reported cash, cash equivalents, and marketable securities of $28.4 million, and total debt outstanding
of $12.5 million. Due to the timing of cash settlements associated with the aforementioned financial transactions that were completed
subsequent to September 30, 2024, pro forma cash was $18.5 million, and pro forma outstanding debt was $11.5 million. The Company’s
strengthened balance sheet, along with our cash conservation strategy and anticipated revenue growth, is expected to provide sufficient
cash runway to support current operating plans through June 2026.
Conference
Call & Webcast
Monday,
November 11th @ 4:30 PM ET
Domestic: | 1-877-407-0784 |
International: | 1-201-689-8560 |
Conference ID: |
13749670 |
Webcast: | A
webcast of the live conference call can be accessed by visiting the Events section of the
Company’s website (click here) or directly (click here). An online replay
will be available on the Company’s website or via the direct link an hour after the
call. |
About
Beyond Air®, Inc.
Beyond
Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous
nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The
Company has received FDA approval for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic
respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of
severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others.
Also, the Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment
of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is
investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting.
For more information, visit www.beyondair.net.
About
LungFit®*
Beyond
Air’s LungFit is a cylinder-free, phasic flow generator and delivery system and has been designated as a medical device by the
U.S. Food and Drug Administration (FDA). The ventilator compatible version of the device can generate NO from ambient air on demand for
delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure
NO cylinders providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements,
improving overall safety with the elimination of NO2 purging steps, and other benefits. LungFit can also deliver NO at concentrations
at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g. COVID-19, bronchiolitis)
and chronic, refractory lung infections in the home setting (e.g. NTM). With the elimination of cylinders, Beyond Air intends
to offer NO treatment in the home setting.
*
Beyond Air’s LungFit PH is approved for commercial use only in the United States of America to treat term and near-term neonates
with hypoxic respiratory failure. Beyond Air’s other LungFit systems are not approved for commercial use and are for investigational
use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.
About
PPHN
Persistent
pulmonary hypertension of the newborn (PPHN) is a lethal condition and secondary to failure of normal circulatory transition at birth.
It is a syndrome characterized by elevated pulmonary vascular resistance (PVR) that causes labile hypoxemia due to decreased pulmonary
blood flow and right-to-left shunting of blood. Its incidence has been reported as 1.9 per 1000 live births (0.4–6.8/1000 live
births) with mortality rate ranging between 4–33%. This syndrome complicates the course of about 10% of infants with respiratory
failure and remains a source of considerable morbidity and mortality. NO gas is a vasodilator, is approved in dozens of countries to
improve oxygenation and reduces the need for extracorporeal membrane oxygenation (ECMO) in term and near-term (>34 weeks gestation)
neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction
with ventilator support and other appropriate agents.
About
Beyond Cancer, Ltd.
Beyond
Cancer, Ltd., an affiliate of Beyond Air, Inc., is a development-stage biopharmaceutical and medical device company utilizing (UNO via
a proprietary delivery platform to treat primary tumors and prevent metastatic disease. Nitric oxide at ultra-high concentrations has
been reported to show anticancer properties and to potentially serve as a chemosensitizer and radiotherapy enhancer. A first-in-human
study is underway in patients with solid tumors. The Company is conducting preclinical studies of UNO in multiple solid tumor models
to inform additional treatment protocols.
For
more information, visit www.beyondcancer.com.
Forward
Looking Statements
This
press release contains “forward-looking statements” concerning the potential safety and efficacy of inhaled nitric oxide
and the ultra-high concentration nitric oxide product candidate, as well as its therapeutic potential in a number of indications; and
the potential impact on patients and anticipated benefits associated with inhaled nitric oxide and the ultra-high concentration nitric
oxide product candidate. Forward-looking statements include statements about expectations, beliefs, or intentions regarding product offerings,
business, results of operations, strategies or prospects. You can identify such forward-looking statements by the words “appears,”
“expects,” “plans,” “anticipates,” “believes” “expects,” “intends,”
“looks,” “projects,” “goal,” “assumes,” “targets” and similar expressions
and/or the use of future tense or conditional constructions (such as “will,” “may,” “could,” “should”
and the like) and by the fact that these statements do not relate strictly to historical or current matters. Rather, forward-looking
statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking
statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could
cause actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking
statements are only predictions and reflect views as of the date they are made with respect to future events and financial performance.
Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking
statements, including risks related to the ability to raise additional capital; the timing and results of future pre-clinical studies
and clinical trials; the potential that regulatory authorities, including the FDA and comparable non-U.S. regulatory authorities, may
not grant or may delay approval for our product candidates; the approach to discover and develop novel drugs, which is unproven and may
never lead to efficacious or marketable products; the ability to fund and the results of further pre-clinical studies and clinical trials
of our product candidates; obtaining, maintaining and protecting intellectual property utilized by products; obtaining regulatory approval
for products; competition from others using similar technology and others developing products for similar uses; dependence on collaborators;
and other risks, which may, in part, be identified and described in the “Risk Factors” section of Beyond Air’s most
recent Annual Report on Form 10-K and other of its filings with the Securities and Exchange Commission, all of which are available on
Beyond Air’s website. Beyond Air and Beyond Cancer undertake no obligation to update, and have no policy of updating or revising,
these forward-looking statements, except as required by applicable law.
CONTACTS:
Investor
Relations contacts
Corey
Davis, Ph.D.
LifeSci
Advisors, LLC
Cdavis@lifesciadvisors.com
(212)
915-2577
BEYOND
AIR, INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED BALANCE SHEETS
(amounts
in thousands, except share and per share data)
| |
September 30, 2024 | | |
March 31, 2024 | |
| |
(Unaudited) | | |
| |
ASSETS | |
| | | |
| | |
Current assets | |
| | | |
| | |
Cash and cash equivalents | |
$ | 28,447 | | |
$ | 11,378 | |
Marketable securities | |
| - | | |
| 23,090 | |
Restricted cash | |
| 230 | | |
| 230 | |
Accounts receivable | |
| 556 | | |
| 319 | |
Inventory, net | |
| 2,527 | | |
| 2,127 | |
Other current assets and prepaid expenses | |
| 6,275 | | |
| 6,792 | |
Total current assets | |
| 38,036 | | |
| 43,936 | |
Licensed right to use technology | |
| 1,325 | | |
| 1,427 | |
Right-of-use lease assets | |
| 1,897 | | |
| 2,121 | |
Property and equipment, net | |
| 11,648 | | |
| 9,364 | |
Other assets | |
| 105 | | |
| 113 | |
TOTAL ASSETS | |
$ | 53,010 | | |
$ | 56,961 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
Current liabilities | |
| | | |
| | |
Accounts payable | |
$ | 1,490 | | |
$ | 1,948 | |
Accrued expenses and other current liabilities | |
| 4,470 | | |
| 8,402 | |
Operating lease liability, current portion | |
| 381 | | |
| 418 | |
Loans payable, current portion | |
| 258 | | |
| 800 | |
Total current liabilities | |
| 6,599 | | |
| 11,567 | |
| |
| | | |
| | |
Operating lease liability, net | |
| 1,690 | | |
| 1,898 | |
Long-term debt, net | |
| 10,940 | | |
| 14,721 | |
Long term liability, related party | |
| 4,427 | | |
| - | |
Warrant Liability | |
| 60 | | |
| 275 | |
Derivative liability | |
| - | | |
| 1,314 | |
Total liabilities | |
| 23,716 | | |
| 29,775 | |
| |
| | | |
| | |
Stockholders’ equity | |
| | | |
| | |
Preferred Stock, $0.0001 par value per share: 10,000,000 shares authorized, 0 shares issued and outstanding | |
| - | | |
| - | |
Common Stock, $0.0001 par value per share: 100,000,000 shares authorized, 72,187,636 and 45,900,821 shares issued and outstanding as of September 30, 2024 and March 31, 2024, respectively | |
| 7 | | |
| 5 | |
Treasury stock | |
| (25 | ) | |
| (25 | ) |
Additional paid-in capital | |
| 293,391 | | |
| 264,780 | |
Accumulated deficit | |
| (265,255 | ) | |
| (239,697 | ) |
Accumulated other comprehensive income (loss) | |
| 9 | | |
| (15 | ) |
Total stockholders’ equity attributable to Beyond Air, Inc | |
| 28,127 | | |
| 25,048 | |
Non-controlling interest | |
| 1,167 | | |
| 2,138 | |
Total equity | |
| 29,294 | | |
| 27,186 | |
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | |
$ | 53,010 | | |
$ | 56,961 | |
BEYOND
AIR, INC. AND SUBSIDIARIES
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(amounts
in thousands, except share and per share data)
(UNAUDITED)
| |
For the Three Months Ended | | |
For the Six Months Ended | |
| |
September 30, | | |
September 30, | |
| |
2024 | | |
2023 | | |
2024 | | |
2023 | |
| |
| | |
| | |
| | |
| |
Revenues | |
$ | 798 | | |
$ | 239 | | |
$ | 1,481 | | |
$ | 298 | |
| |
| | | |
| | | |
| | | |
| | |
Cost of revenues | |
| 1,882 | | |
| 432 | | |
| 2,897 | | |
| 735 | |
| |
| | | |
| | | |
| | | |
| | |
Gross loss | |
| (1,084 | ) | |
| (193 | ) | |
| (1,416 | ) | |
| (437 | ) |
| |
| | | |
| | | |
| | | |
| | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
Research and development | |
| (4,585 | ) | |
| (7,130 | ) | |
| (10,594 | ) | |
| (11,826 | ) |
Selling, general and administrative | |
| (7,163 | ) | |
| (10,211 | ) | |
| (14,402 | ) | |
| (21,147 | ) |
Total Operating expenses | |
| (11,748 | ) | |
| (17,342 | ) | |
| (24,995 | ) | |
| (32,972 | ) |
| |
| | | |
| | | |
| | | |
| | |
Loss from Operations | |
| (12,833 | ) | |
| (17,535 | ) | |
| (26,412 | ) | |
| (33,410 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income (expense) | |
| | | |
| | | |
| | | |
| | |
Dividend/interest income | |
| 150 | | |
| 641 | | |
| 511 | | |
| 1,050 | |
Interest and finance expense | |
| (927 | ) | |
| (914 | ) | |
| (1,891 | ) | |
| (1,072 | ) |
Change in fair value of warrant liability | |
| (4 | ) | |
| 324 | | |
| 214 | | |
| 647 | |
Change in fair value of derivative liability | |
| 256 | | |
| 500 | | |
| 1,314 | | |
| 1,012 | |
Foreign exchange gain/ (loss) | |
| 74 | | |
| (42 | ) | |
| (72 | ) | |
| (34 | ) |
Loss on extinguishment of debt | |
| (624 | ) | |
| - | | |
| (624 | ) | |
| - | |
Loss on disposal of fixed assets | |
| (171 | ) | |
| - | | |
| (171 | ) | |
| - | |
Estimated liability for contingent loss | |
| - | | |
| (400 | ) | |
| - | | |
| (598 | ) |
Other income / (expense) | |
| 49 | | |
| - | | |
| 48 | | |
| (77 | ) |
Total other income/ (expense) | |
| (1,196 | ) | |
| 109 | | |
| (671 | ) | |
| 929 | |
| |
| | | |
| | | |
| | | |
| | |
Net loss before income taxes | |
$ | (14,029 | ) | |
$ | (17,426 | ) | |
$ | (27,083 | ) | |
$ | (32,481 | ) |
| |
| | | |
| | | |
| | | |
| | |
Provision for income taxes | |
| - | | |
| - | | |
| - | | |
| - | |
| |
| | | |
| | | |
| | | |
| | |
Net loss | |
$ | (14,029 | ) | |
$ | (17,426 | ) | |
$ | (27,083 | ) | |
$ | (32,481 | ) |
| |
| | | |
| | | |
| | | |
| | |
Less : net loss attributable to non-controlling interest | |
| (671 | ) | |
| (1,205 | ) | |
| (1,525 | ) | |
| (2,165 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss attributable to Beyond Air, Inc. | |
| (13,358 | ) | |
| (16,220 | ) | |
| (25,559 | ) | |
| (30,315 | ) |
| |
| | | |
| | | |
| | | |
| | |
Foreign currency translation loss | |
| (79 | ) | |
| (35 | ) | |
| 24 | | |
| (9 | ) |
Comprehensive loss attributable to Beyond Air, Inc. | |
$ | (13,438 | ) | |
$ | (16,255 | ) | |
$ | (25,535 | ) | |
$ | (30,325 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net basic and diluted loss per share attributable to Beyond Air, Inc. | |
$ | (0.28 | ) | |
$ | (0.51 | ) | |
$ | (0.55 | ) | |
$ | (0.96 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average number of shares, outstanding, basic and diluted | |
| 47,118,535 | | |
| 31,800,492 | | |
| 46,513,005 | | |
| 31,592,880 | |
v3.24.3
Cover
|
Nov. 11, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Nov. 11, 2024
|
Entity File Number |
001-38892
|
Entity Registrant Name |
Beyond
Air, Inc.
|
Entity Central Index Key |
0001641631
|
Entity Tax Identification Number |
47-3812456
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
900
Stewart Avenue
|
Entity Address, Address Line Two |
Suite 301
|
Entity Address, City or Town |
Garden
City
|
Entity Address, State or Province |
NY
|
Entity Address, Postal Zip Code |
11530
|
City Area Code |
(516)
|
Local Phone Number |
665-8200
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, par value $.0001 per share
|
Trading Symbol |
XAIR
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Beyond Air (NASDAQ:XAIR)
Historical Stock Chart
From Nov 2024 to Dec 2024
Beyond Air (NASDAQ:XAIR)
Historical Stock Chart
From Dec 2023 to Dec 2024